AU2001288485A1 - Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists - Google Patents

Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists

Info

Publication number
AU2001288485A1
AU2001288485A1 AU2001288485A AU8848501A AU2001288485A1 AU 2001288485 A1 AU2001288485 A1 AU 2001288485A1 AU 2001288485 A AU2001288485 A AU 2001288485A AU 8848501 A AU8848501 A AU 8848501A AU 2001288485 A1 AU2001288485 A1 AU 2001288485A1
Authority
AU
Australia
Prior art keywords
antagonists
beta
alpha
ring system
compounds containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288485A
Inventor
Balekudru Devadas
Ish Kumar Khanna
Hwang Fun Lu
S. Chandrakumar Nizal
Yi Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001288485A1 publication Critical patent/AU2001288485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001288485A 2000-08-29 2001-08-29 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists Abandoned AU2001288485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22869300P 2000-08-29 2000-08-29
US60228693 2000-08-29
PCT/US2001/026889 WO2002018377A1 (en) 2000-08-29 2001-08-29 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists

Publications (1)

Publication Number Publication Date
AU2001288485A1 true AU2001288485A1 (en) 2002-03-13

Family

ID=22858209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288485A Abandoned AU2001288485A1 (en) 2000-08-29 2001-08-29 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists

Country Status (6)

Country Link
US (2) US20040058915A1 (en)
EP (1) EP1320530A1 (en)
JP (1) JP2004521079A (en)
AU (1) AU2001288485A1 (en)
CA (1) CA2419255A1 (en)
WO (1) WO2002018377A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376161T3 (en) * 2001-01-29 2012-03-09 Janssen Pharmaceuticals, Inc. SUBSTITUTE INDOLES AND THEIR USE AS AN INTEGRINE ANTAGONISTS.
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp Indole acetic acid derivatives and their use as pharmaceutical agents
CN1874991A (en) 2003-08-29 2006-12-06 小野药品工业株式会社 Compound capable of binding S1P receptor and pharmaceutical use thereof
CA2537093C (en) * 2003-08-29 2013-11-12 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
BRPI0419110A (en) * 2004-10-14 2007-12-11 Pharmacia Corp biphenyl integrin antagonists
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
EP2371811B1 (en) * 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EP2123644B1 (en) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
US9345739B2 (en) * 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
CN103096977B (en) 2010-07-02 2017-02-15 吉利德科学公司 Fused heterocyclic compounds as ion channel modulators
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
TWI549944B (en) 2011-07-01 2016-09-21 吉李德科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
DK3929196T3 (en) 2013-09-24 2023-09-25 Fujifilm Corp PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF OR METAL COMPLEX THEREOF
SG11202004077WA (en) * 2017-11-07 2020-05-28 Bristol Myers Squibb Co Pyrrolopyrazine derivatives as alpha v integrin inhibitors
US20210277051A1 (en) * 2018-06-22 2021-09-09 Zhejiang Peptites Biotech Co., Ltd. Compound or salt thereof and preparation method and application of same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
BR9508178A (en) * 1994-06-29 1997-11-18 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vitronectin receptor antagonists
US5602155A (en) * 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2002510328A (en) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
HUP0003949A2 (en) * 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronectin receptor antagonist and pharmaceutical composition containing the compounds
DE10006139A1 (en) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl derivatives

Also Published As

Publication number Publication date
US20020072518A1 (en) 2002-06-13
JP2004521079A (en) 2004-07-15
WO2002018377A1 (en) 2002-03-07
EP1320530A1 (en) 2003-06-25
US20040058915A1 (en) 2004-03-25
CA2419255A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
AU2001288485A1 (en) Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
AU2001252574A1 (en) Novel bicyclic compounds
AU5648899A (en) Fused ring compound
IL145071A0 (en) Fused ring compounds and pharmaceutical compositions containing the same
EP1155764A4 (en) Combined nc lathe
AU3899997A (en) Muscarinic antagonists
AU3953795A (en) Bicyclic neuropeptide y receptor antagonists
AU1441695A (en) Fibrinogen receptor antagonists
AU1400095A (en) Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
AU2001259707A1 (en) 6,5-fused bicyclic heterocycles
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
AU4746297A (en) Vitronectin receptor antagonists
AU5577096A (en) Sulfonylquinolines as neuropeptide y1 antagonists
AU3044197A (en) Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
HUP0104452A3 (en) Medicinal compositions, containing tricyclo compounds
AU4261293A (en) 1-piperazineacetic derivatives as fibrinogen receptor antagonists
AU3840000A (en) Tricyclic compounds
CZ20012069A3 (en) Antihistamine spiro compounds
AU5852300A (en) Heteroaromatic ring compounds
AU3041700A (en) Imidazo(4,5-c)-pyridine-4-on-derivatives
AU2759892A (en) N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
AU5781998A (en) Split ring for fishing
AU3057299A (en) Sustained-release composition containing cefaclor
GB2348558A8 (en) GPS for workstations
AU5786300A (en) Muscarinic antagonists